Impact of nutritional treatment in the evolution of inflammatory bowel disease;Impacto de la nutrición en la evolución de la enfermedad inflamatoria intestinal

Nutricion Hospitalaria

Volumn 25, Issue 2, 2010, Pages 181-192

  Pomar, M D Ballesteros ^a   Casariego, A Vidal ^a   Fernández, A Calleja ^a   Gómez, J J López ^a   Fondo, A Urioste ^a   Rodríguez, I Cano ^a  

^a Complejo Asistencial Universitario de León   (Spain)

Author keywords

Chron's disease; Enteral nutrition; Inflammatory bowel disease; Probiotics; Ulcerative colitis

Indexed keywords

PROBIOTIC AGENT;

DIET THERAPY; ENTERITIS; HUMAN; REMISSION; REVIEW;

HUMANS; INFLAMMATORY BOWEL DISEASES; NUTRITION THERAPY; PROBIOTICS; REMISSION INDUCTION;

EID: 77950335457     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2010.25.2.4295     Document Type: Review

References (83)

1. Brullet E, Bonfill X, Urrutia G, Ruiz Ochoa V, Cueto M, Clofent J y cols. Estudio epidemiológico de la incidencia de enfermedad inflamatoria intestinal en 4 áreas de España. Med Clin 1998; 17: 651-656
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429
3. Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care 2001; 4: 561-569
4. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: v1-v16.
5. Cabré E, Gassul MA. Nutrition in inflammatory bowel disease: impact on disease and therapy. Curr Opin Gastroenterol 2001; 17: 342-349
6. Cabré Gelada E. Nutrición y enfermedad inflamatoria intestinal. Nutr Hosp 2007; 22 (Supl. 2): 65-73.
7. Pérez Tárrago C, Puebla Maestu A, Miján de la Torre A. Tratamiento nutricional en la enfermedad inflamatoria intestinal. Nutr Hosp 2008; 23 (5): 417-427
8. Arrizabalaga JJ. Manejo nutricional de la enfermedad inflamatoria intestinal. Endocrinol Nutr 2007; 54 (3): 151-168
9. Campos FG, Waitzberg DL, Teixeira MG, Mucerino DR, Kiss DR, Habr-Gama A. Pharmacological Nutrition in Inflammatory Bowel Diseases. Nutr Hosp 2003; 18: 57-64.
10. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988; 29: 1309-1315
11. Payne-James JJ, Silk DBA.Total parenteral nutrition as primary treatment in Crohn's disease-RIP? Gut 1988; 29: 1304-1308
12. Lomer MCE, Harvey RSJ, Evans SM y cols. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur J Gastroenterol Hepatol 2001; 13: 101-106
13. Mahmud N, Weir DG. The urban diet and Crohn's disease: is there a relationship? Eur J Gastroenterol Hepatol 2001; 13: 93-95
14. O'Moráin C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. BMJ 1984; 288: 1859-1862
15. Zachos M, Tondeur M, Griffiths AM. Nutrición enteral para la inducción de la remisión en la enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.). Acceso 28 de diciembre de 2008.
16. Fernández Bañares F, Cabré E, Esteve Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN 1995; 19: 356-364
17. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Metaanalysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108: 1056-1067
18. Messori A, Trallori G, D'Albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula diets versus steroids in the treatment of active Crohn's disease-A meta-analysis. Scand J Gastroenterol 1996; 31: 267-272
19. Griffiths AM. Enteral feeding in inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care 2006; 9: 314-318
20. Akobeng AK, Miller V, Stanton J y cols. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000; 30: 78-84.
21. Fell JM. Control of systemic and local inflammation with transforming growth factor beta containing formulas. J Parenter Enteral Nutr 2005; 29: S126-8.
22. Fell JME, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P y cols. Mucosal healing and a fall in mucosal proinflammatory cytokine mRNA induced by a specific oral polymeric diet in pediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-289
23. Gorard DA. Enteral nutrition in Crohn's disease: fat in the formula. Eur J Gastro Hepatol 2003; 15: 115-118
24. MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W y cols. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005; 82: 611-619
25. Gassull MA, Fernández-Bañares F, Cabré E, Papo M, Giaffer MH, Sánchez-Lombraña JL y cols. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut 2002; 51: 164-168
26. González-Huix F, De León R, Fernández Bañares F, Esteve M, Cabré E, Acero D y cols. Polymeric enteral diet as primary treatment of active Crohn's disease-A prospective steroid controlled trial. Gut 1993; 34: 778-782
27. Newby EA, Sawczenko A, Thomas AG, Wilson D. Intervenciones frente al retraso del crecimiento en niños con enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2005 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com (Traducida de The Cochrane Library, 2005 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.). Acceso 5 de enero de 2009.
28. Dziechciarz P, Horvath A, Shamir R, Szajewska H. Metaanalysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 2007; 26: 795-806.
29. Heuschkel RB. Enteral nutrition in children with Crohn's disease. J Pediatr Gastroenterol Nutr 2000; 31: 575.
30. Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr 2004; 93: 327-335
31. Sánchez-Valverde F. Tratamiento nutricional de la enfermedad inflamatoria intestinal. Acta Pediatr Esp2006; 64: 22-26
32. Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003; 9: 34-58.
33. Ruemmelle FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? J Pediatr 2000; 136: 285-291
34. Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment Pharmacol Ther 2008; 27: 11-18
35. Akobeng AK, Thomas AG. Nutrición enteral para el mantenimiento de la remisión en la enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.). Acceso 28 de diciembre de 2008.
36. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M y cols. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. Aliment Pharmacol Ther 2006; 24 (9): 1333-1340
37. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand J Gastroenterol 2001; 36 (4): 383-388
38. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M y cols. Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease. The EPIC Randomized Controlled Trials. JAMA 2008; 299: 1690-1697
39. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007; (2): CD006320.
40. Lochs H, Dejong C, Hammarqvist F, Hebuterne X, León-Sanz M, Schütz T y cols. ESPEN guidelines on enteral nutrition: Gastroenterology. Clinical nutrition 2006; 25: 260-274
41. Fernández-Bañares F, Hinojosa J, Sánchez- Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A y cols. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433
42. De Ley M, De Vos R, Hommes DW, Stokkers P. Aceite de pescado para la inducción de remisión en la colitis ulcerosa (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en:http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.). Acceso 4 de enero de 2009.
43. Turner D, Steinhart AH, Griffiths AM. Ácidos grasos omega-3 (aceite de pescado) para el mantenimiento de la remisión en la colitis ulcerosa (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd.Disponible en:http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.). Acceso 4 de enero de 2009.
44. Shah S. Dietary Factors in the Modulation of Inflammatory Bowel Disease Activity. Medscape General Medicine. 2007;9(1):60. http://www.medscape.com/ viewarticle/553039. Acceso 10 de enero de 2009.
45. Shanahan F. Inflammatory Bowel Disease: Immunodiagnostics, Immunotherapeutics, and Ecotherapeutics. Gastroenterology 2001; 120: 622-635
46. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995; 24: 475-507.
47. Borruel Sainz N. ¿Son útiles los prebióticos en la enfermedad inflamatoria intestinal? EN: Estrategias clínicas en Digestivo. Acceso 25 de enero de 2007. http://www.prous.com/digest/ digest06-05/ponents.cfm?spk=bor&sli=14.
48. Penner RM, Fedorak RN. Probiotics in the Management of Inflammatory Bowel Disease. Medscape General Medicine. 2005;7(3):19. Acceso 26 de enero de 2007.http://www.meds-cape.com/viewarticle/504680.
49. Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006; 40 (3): 260-263
50. Butterworth AD, Thomas AG, Akobeng AK. Probióticos para la inducción de la remisión en la enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
51. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5.
52. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004826. DOI: 10.1002/14651858.CD004826.pub2. (Pubitemid 46841294)
53. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25 (4): 653-658
54. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409
55. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55 (6): 842-847
56. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F y cols. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 2007; 13 (2): 135-142
57. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639
58. Kato K, Mizuno S, Umesaki Y y cols. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141
59. Furrie E, Macfarlane S, Kennedy A y cols. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut2005; 54: 242-249
60. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccha-romyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698
61. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M y cols. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100 (7): 1539-1546
62. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858
63. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M y cols. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
64. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
65. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E,Brigidi P y cols. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108
66. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10 (11): PI126-31.
67. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M y cols. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23 (11): 1567-1574
68. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G y cols. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology2000; 119: 305-309
69. Mimura T, Helwig U, Paggioli G, Schreiber S, Talbot IC, Nicholls RJ y cols. One daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut2004; 53: 108-114
70. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM,Brigidi P y cols. Prophylaxis of pouchitis onset with probiotic therapy: a double-bland, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209
71. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial microbiota. Aliment Pharmacol Ther 2001; 17: 509-515
72. Gosselink MP, Schouten WR, Van Lieshout LM, Hop WC, Laman JD, Ruseler-Van Embden JG. Delay of first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47: 876-884
73. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proceedings of the Nutrition Society 2007; 66: 307-315
74. Bengmark S. Pre-, pro-and synbiotics. Curr Opin Clin Nutr Metabol Care 2001; 4: 571-579
75. SchrezenmeirJ, De Vrese M. Probiotics,prebiotics, and synbiotics - approaching a definition. Am J Clin Nutr 2001; 73 (2Supl.): 361-364
76. Burke A, Lichtenstein GR, Rombeau JL. Nutritional and metabolic advances in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 1998; 1: 387-390
77. Lindsay, JO, Whelan, K, Stagg, AJ y cols. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55: 348.
78. Kanauchi O, Suga T, Tochihara M y cols. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002; 37 (Supl. 14): 67-72.
79. Welters CFM, Heineman E, Thunnissen FBJM y cols. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum2002; 45: 621-627
80. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA y cols. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut2005; 54: 242-249
81. Fernández-Banares F, Hinojosa J, Sanchez-Lombrana JL y cols. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish group for the study of crohn's disease and ulcerative colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433
82. Guarner F. Prebiotics in inflammatory bowel diseases. Br J Nutri 2007; 98: S85-S89.
83. Sartor R. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633